Results 111 to 120 of about 291,920 (218)

CAR-NK cell therapy for hematological malignancies. [PDF]

Blood Adv
Manzar GS, Hasan MF, Moore M, Tiberti S, Basar R, Daher M.   +5 more
europepmc   +1 more source

TP53 Loss Elevates NF-κB-IFN-β-MHC-Ia Signaling to Promote NK Cell Resistance in Osteosarcoma. [PDF]

Adv Sci (Weinh)
TP53 loss in a transforming or osteosarcoma cell promotes cytosolic DNA accumulation, activating NF‐κB‐dependent IFN‐β production. Autocrine IFN‐β signaling increases cell‐surface HLA‐Ia expression, strengthens inhibitory KIR signaling in natural killer cells, and thereby enables the affected cell to evade NK cell‐mediated cytotoxicity.
Qin G, Yeung CK, Yi Y, Zheng D, Ye M, Chio CC, Wu J, Fu S, Deng CX, Xu RH.   +9 more
europepmc   +2 more sources

CHST1 Drives Immunotherapy Resistance in Triple‐Negative Breast Cancer by Orchestrating an Immunosuppressive Microenvironment via the NKRF–CCL20–Macrophage Axis

Advanced Science, EarlyView.
Proposed model of CHST1‐associated immune remodeling in triple‐negative breast cancer. In CHST1‐low tumors, greater nuclear accumulation of NKRF is associated with repression of an NF‐κB‐related CCL20 transcriptional program and an immune‐inflamed microenvironment.
Shu‐Hao Jiang, Xiao‐Han Ying, Ruo‐Qing Wang, Qun Zhang, Li Chen, Zhi‐Ming Shao, Jun‐Jie Li   +6 more
wiley   +1 more source

HDAC6 orchestrates NK cell maturation and antitumor immunity. [PDF]

J Immunother Cancer
Yang W, Tian P, Guo X, Ding M, Xiao R, Wu Z, Yue X, Li C, Gao L, Zhou J, Ma CH, Li X, Wang J, Liang X.   +13 more
europepmc   +1 more source

Intrasplenic Thymus Organogenesis from Injectable Tissue Fragments Restores Functional T‐Cell Immunity

Advanced Science, EarlyView.
Clinical intramuscular thymus transplantation yields only short‐lived efficacy and marginal therapeutic benefits. Benefiting from the spleen's intrinsic strengths—rapid vascular perfusion, abundant developmental factors, and resident progenitors—the intrasplenic thymic grafts achieve robust thymic regeneration and substantial T‐cell reconstitution ...
Shaocong Wang, Zijian Zhang, Fulin Dai, Zhijie Yin, Zhen Xing, Yurong Li, Haochong Lei, Junfeng Zhang, Chunyan Liu, Yan Li, Lei Dong   +10 more
wiley   +1 more source

Macrophage PABPC4‐SPP1 Axis Orchestrates Immunosuppression in Colorectal Cancer

Advanced Science, EarlyView.
In the CRC microenvironment, macrophage PABPC4 binds to the 3′UTR of SPP1 mRNA to stabilize its expression, thereby sustaining M2‐like immunosuppressive macrophage polarization. Concurrently, this axis suppresses CD8+ T cell effector functions via CD44 signaling, collectively fostering an immunosuppressive niche that drives tumor progression.
Meng Wang, Fang Yang, Yuan Gao, Liuli Li, Yulan Huang, Hui Yao, Sijie Zhao, Kun Zhao, Tianying Zhang, Hui Heng, Jiaxin Xu, Yuancai Xiang, Weidong Xiao, Shaofan Hu, Hongming Miao   +14 more
wiley   +1 more source

Corrigendum to "Mechanisms of tumor cell evasion from NK cell-mediated killing and advances in NK cell-based cancer immunotherapy" [Pharm. Sci. Adv. 4 (2026) 100109]. [PDF]

Pharm Sci Adv
Zheng R, Wang Z, Zhang B, Li Y, Gao S, Guo Y, Meng D, Mu X, Shao L.   +8 more
europepmc   +1 more source

SerpinA3 is an Endogenous TGF‐β Receptor Antagonist that Attenuates Cardiac Fibroblast Activation and Fibrotic Remodeling

Advanced Science, EarlyView.
SerpinA3 acts as an endogenous TGF‐β receptor antagonist that binds to the extracellular domain of TGFR‐1, thereby preventing TGFR‐1–TGFR‐2 complex formation. This receptor‐level blockade suppresses TGF‐β/Smad2/3 signaling, attenuates cardiac fibroblast activation, and extracellular matrix deposition, and ultimately alleviates pressure overload–induced
Hui Wang, Jieyu Cui, Chunlu Huang, Wanyi Guo, Tong Liu, Yi Zhu, Shuai Shao, Kangyin Chen, Jinlong He, Qiankun Bao   +9 more
wiley   +1 more source

PTPN22 as a novel therapeutic target: a key intracellular checkpoint for NK cell therapy. [PDF]

J Immunother Cancer
Uong TNT, Yoon M, Nguyen NPNM, Lee M, Koh SK, Jeong JU, Kim YH, Cho D.   +7 more
europepmc   +1 more source

Potential of Nanoparticle‐Based Phototherapies for Future Treatment of Uveal Melanoma

Advanced Science, EarlyView.
This review evaluates nanoparticle‐based phototherapies for uveal melanoma, highlighting emerging strategies to enhance tumor targeting, light delivery, and treatment precision. Preclinical data indicate improved efficacy and reduced toxicity, supporting their potential to enhance localized treatment and future translational advances. (Generated by the
Emilie Lambert, Christophe Nguyen, Sean Edward Dunn, Magali Gary‐Bobo, Jérôme Lacombe, Justin Moser, Frédéric Zenhausern, Jean‐Olivier Durand, Frédérique Cunin   +8 more
wiley   +1 more source